ArticleEndocrinology, diabetes & metabolism case reports2025
From genotype to phenotype: the impact of early management in pycnodysostosis.
Article in Endocrinology, diabetes & metabolism case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Summary: Pycnodysostosis (PYCD) is an osteosclerotic skeletal dysplasia caused by mutations in the CTSK gene. We describe four cases, highlighting their clinical progression and therapeutic responses. Case 1 is a 2-year-old girl with non-consanguineous parents exhibiting short stature (Z-score: -3.23), slow growth (3 cm/year), wide fontanelles, small hands, and no fractures. She received cholecalciferol and calcium. Two CTSK variants (c.436G>C; p.Gly146Arg and c.721C>T; p.Arg241*) were identified. At age three, somatropin was initiated, leading to improved growth (8 cm/year) and a stature Z-score of -2.21, without fractures until age six. Case 2 is a 2-year-old boy, sibling of Case 1, presenting with similar findings (Z-score: -1.81). Carrying the same CTSK variants, he showed improved growth (3 cm/4 months) after growth hormone therapy. Case 3 is a 3-year-old boy with consanguineous parents having short stature (Z-score: -3.75), slow growth (2 cm/year), exophthalmos, bluish sclera, and multiple tibial fractures. A homozygous CTSK variant (c.953G>A; p.Cys318Tyr) was identified. Growth hormone at age six, alongside cholecalciferol and calcium, increased growth (7 cm/year) and improved stature (Z-score: -2.65). Case 4 is an 8-year-old girl with consanguineous parents having multiple fractures, exophthalmos, and severe growth impairment. Misdiagnosed with osteogenesis imperfecta, she received bisphosphonates, further compromising bone integrity. While genotype defines PYCD, early intervention can modulate its phenotype. Growth hormone, calcium, and cholecalciferol improved growth, whereas bisphosphonates negatively impacted bone quality. Learning points: CTSK mutations define PYCD, but patients exhibit diverse skeletal features, necessitating individualized management. Despite normal IGF-1, growth hormone therapy enhances growth velocity and final height in selected PYCD cases. Bisphosphonates may worsen bone remodeling in PYCD, increasing fracture risk and impairing growth. The CTSK c.953G>A (p.Cys318Tyr) variant correlates with severe skeletal manifestations and variable treatment response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.